JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

྾

Home
Applications
Targets
Kinases
CAMK:Calcium/calmodulin-dependent protein kinases
Galapagos MAPKAPK5 inhibitor D , CAS No.G610472, Inhibitor of MAPK activated protein kinase 5

Galapagos MAPKAPK5 inhibitor D , CAS No.G610472, Inhibitor of MAPK activated protein kinase 5

Item Number

G610472

Grouped product items
SKU	Size	Availability	Price	Qty
G610472-5mg	5mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$580.90
G610472-25mg	25mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$2,000.90

View related series

Basic Description

Synonyms	959754-85-9\|GLPG0259\|4-(8-((4-(4-(tert-Butyl)piperazin-1-yl)phenyl)amino)-[1,2,4]triazolo[1,5-a]pyrazin-5-yl)furan-2-carboxamide\|Galapagos MAPKAPK5 inhibitor D\|4-[8-[4-(4-tert-butylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]furan-2-carboxa
Grade	Moligand™
Action Type	INHIBITOR
Mechanism of action	Inhibitor of MAPK activated protein kinase 5

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

IUPAC Name	4-[8-[4-(4-tert-butylpiperazin-1-yl)anilino]-[1,2,4]triazolo[1,5-a]pyrazin-5-yl]furan-2-carboxamide
INCHI	InChI=1S/C24H28N8O2/c1-24(2,3)31-10-8-30(9-11-31)18-6-4-17(5-7-18)29-22-23-27-15-28-32(23)19(13-26-22)16-12-20(21(25)33)34-14-16/h4-7,12-15H,8-11H2,1-3H3,(H2,25,33)(H,26,29)
InChi Key	DLGZLIXYVSQGOX-UHFFFAOYSA-N
Canonical SMILES	NC(=O)c1occ(c1)c1cnc(c2n1ncn2)Nc1ccc(cc1)N1CCN(CC1)C(C)(C)C
Isomeric SMILES	CC(C)(C)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(N4C3=NC=N4)C5=COC(=C5)C(=O)N
PubChem CID	57589985

PubChem CID	57589985

Enter Lot Number to search for COA:

1. Westhovens R, Keyser FD, Rekalov D, Nasonov EL, Beetens J, Van der Aa A, Wigerinck P, Namour F, Vanhoutte F, Durez P. (2013) Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial.. Ann Rheum Dis, 72 (5): (741-4). [PMID:23161899]

Determine the necessary mass, volume, or concentration for preparing a solution.

Determine the dilution needed to prepare a stock solution.